Physician profile
Jaykumar R Thumar
NPI 1629259932
$18,727.10
in general payments reported to CMS, 2019-2025
18 companies · $8,152 in 2025
The $8,152 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.58 · 2020: $3,475 · 2021: $3,477 · 2022: $3,004 · 2024: $595 · 2025: $8,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,569 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,108 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,568.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,108.00 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,865.00 | 2021-2025 | Imfinzi |
| Abbvie INC. | $2,968.75 | 2025 | |
| Jazz Pharmaceuticals INC. | $2,108.00 | 2025 | |
| Lilly USA, LLC | $1,800.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $1,795.00 | 2020-2024 | |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Taiho Oncology, INC. | $1,400.00 | 2025 | |
| Kite Pharma, INC. | $1,300.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $964.25 | 2022 | |
| Beigene USA, INC. | $525.00 | 2022 | |
| Beigene, Ltd. | $450.00 | 2020 | |
| Seagen INC. | $24.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.60 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaykumar Thumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.